Blood test finds hidden cancer; new drug aims to stop it
NCT ID NCT06680596
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study is for people with a certain type of advanced breast cancer (HR+, HER2-low). First, a blood test looks for leftover cancer DNA after one month of standard hormone therapy and a CDK4/6 inhibitor. Those with positive results then receive trastuzumab deruxtecan, a targeted drug, to see if it can keep the cancer from growing. The goal is to control the disease, not to cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Eugene Marquis
Rennes, France
-
Centre Hospitalier Alpes Léman
Contamine-sur-Arve, 74130, France
-
Centre Hospitalier D'Auxerre
Auxerre, 89000, France
-
Centre Hospitalier William Morey
Chalon-sur-Saône, 71100, France
-
Centre Hospitalier de Beauvais
Beauvais, 60021, France
-
Centre Hospitalier de Cholet
Cholet, 49300, France
-
Centre Hospitalier de Pau
Pau, 64046, France
-
Centre Hospitalier de la Côte Basque
Bayonne, 64100, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Chd Vendée
La Roche-sur-Yon, 85925, France
-
Chi Fréjus-Saint-Raphaël
Fréjus, 83608, France
-
Chp Saint-Grégoire - Groupe Vivalto Sante
Saint-Grégoire, 35760, France
-
Chu Amiens Picardie
Amiens, 80054, France
-
Chu de Brest - Hôpital Cavale Blanche
Brest, 29200, France
-
Clinique Pasteur Lanroze - Cfro - Groupe Vivalto Sante
Brest, 29200, France
-
Clinique Sainte-Anne - Gh Saint-Vincent
Strasbourg, 67000, France
-
Clinique de L'Europe Amiens - Cthe
Amiens, 80090, France
-
Clinique de La Sauvegarde
Lyon, 69009, France
-
Groupe Hospitalier Diaconesses Croix Saint-Simon
Paris, 75020, France
-
Gustave Roussy
Villejuif, France
-
Hopital Prive Jean Mermoz
Lyon, 69008, France
-
Hopital Privé Des Côtes D'Armor (Hpca) - Cario
Plérin, 22190, France
-
Hôpital Saint-Louis
Paris, 75010, France
-
Hôpital Simone Veil de Blois
Blois, 41000, France
-
Hôpitaux Du Léman
Thonon-les-Bains, 74200, France
-
Icm Val D'Aurelle
Montpellier, 34298, France
-
Institut Godinot
Reims, 51100, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, 054519, France
-
Medipôle de Nancy - Cog-Ilc (Polyclinique de Gentilly)
Nancy, 54100, France
-
Pôle Santé République (Elsan)
Clermont-Ferrand, 63000, France
-
Sainte Catherine Institut Du Cancer Avignon Provence
Avignon, 84918, France
Conditions
Explore the condition pages connected to this study.